XRTX Stock Overview
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.78 |
| 52 Week High | CA$3.00 |
| 52 Week Low | CA$0.78 |
| Beta | 0.32 |
| 1 Month Change | -30.36% |
| 3 Month Change | -30.36% |
| 1 Year Change | -64.71% |
| 3 Year Change | -52.54% |
| 5 Year Change | -80.74% |
| Change since IPO | -86.71% |
Recent News & Updates
Recent updates
Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation
Aug 23
XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business
Apr 01We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow
Dec 16Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth
Sep 01Shareholder Returns
| XRTX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -19.6% | -3.7% | 0.6% |
| 1Y | -64.7% | -59.1% | -0.6% |
Return vs Industry: XRTX underperformed the Canadian Pharmaceuticals industry which returned -59.1% over the past year.
Return vs Market: XRTX underperformed the Canadian Market which returned -0.6% over the past year.
Price Volatility
| XRTX volatility | |
|---|---|
| XRTX Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 19.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: XRTX is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: XRTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Allen Davidoff | https://www.xortx.com |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc. Fundamentals Summary
| XRTX fundamental statistics | |
|---|---|
| Market Cap | CA$11.22m |
| Earnings (TTM) | CA$2.53m |
| Revenue (TTM) | n/a |
4.4x
P/E Ratio0.0x
P/S RatioIs XRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRTX income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | -CA$2.53m |
| Earnings | CA$2.53m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XRTX perform over the long term?
See historical performance and comparison